• Matricelf received FDA written feedback backing key elements of a proposed first-in-human NewRal trial in traumatic spinal cord injury.
• No clinical results were presented; the feedback guides preparations for a future IND submission.
• FDA support covered the target patients and a single-arm, open-label design focused on initial safety and tolerability.
• Exploratory measures may be used to gauge potential functional change, but the study’s main outcome is safety evaluation.
• FDA flagged added work for the IND package, including stopping rules and more detail on surgery and imaging selection.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Matricelf Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202609030850PR_NEWS_USPR_____IO40204) on September 03, 2026, and is solely responsible for the information contained therein.